We need to continue to advance the collaborative nature of the partnerships between Health Canada, INESSS, PMPRB and pCPA. We need to be willing to be innovative and try new things. This aligned review...I think you heard from the people who presented from Health Canada. It really started from a conversation between two people that we could accelerate this process. Rather than having sequential processes, we now run them in parallel at the request of the manufacturer. It's a voluntary initiative.
We need to be willing to try to do those things, and to be able to learn when they don't work, and to build on them when they do, first and foremost.
Secondly, we also need to be able to work with the provinces to understand, from their perspective, the kind of data and information that they need in order to publicly reimburse medications. Some of those conversations are already taking place.
Thirdly, we need to be able to continue to advance in this health technology management approach. What that means is a full life-cycle approach for drugs; that not only do we review them, and then provinces, if they have the ability to fund, fund them, but we then keep an eye on how they function in the real world. We need to collect evidence and bring that back into the HTA process to reassess the clinical and economic value of that drug, and make a different choice, if that's the best decision for Canadians.
If we're not seeing the clinical outcomes that we expected to see, that we negotiate again, either working with PMPRB or pCPA, and potentially, for a very small number of drugs where they truly don't perform, if they don't perform, to have the ability to reinvest funding from those drugs into drugs that we know are doing a better job for Canadians. We need to continue doing a lot of the things that we're already starting to do.